Literature DB >> 23283085

High-dose norepinephrine treatment: determinants of mortality and futility in critically ill patients.

Donna Döpp-Zemel1, A B Johan Groeneveld.   

Abstract

BACKGROUND: Critically ill patients with circulatory shock sometimes need rescue treatment with high doses of norepinephrine, a treatment that may be associated with a poor outcome because of excessive vasoconstriction.
OBJECTIVE: To evaluate the outcome of treatment and its determinants in patients with circulatory shock who received high doses of norepinephrine in the intensive care unit and to identify indicators of futility for the treatment.
METHODS: A retrospective study was done on 113 consecutive patients with circulatory shock who received 0.9 μg/kg per minute or greater of norepinephrine during at least 1 hour at any time in the intensive care unit. Data were extracted from the electronic patient data management system according to a predefined checklist.
RESULTS: A total of 39 patients survived for 28 days after admission to the intensive care unit. The variables independently associated with 28-day mortality in multivariable models included low urine flow, high lactate levels, high organ failure score, high prothrombin time, and need for epinephrine cotreatment. The reason, dose, and duration of norepinephrine administration did not have prognostic significance. Scores greater than 40 on the Acute Physiology and Chronic Health Evaluation II, bicarbonate levels less than 9.0 mEq/L, or receipt of an epinephrine dose of 0.25 μg/kg per minute or greater were associated with 100% mortality.
CONCLUSIONS: Although the cause of shock and treatment with norepinephrine were not predictive of death when high doses of the drug were deemed necessary, rescue treatment with high-dose norepinephrine is futile in patients with severe disease and metabolic acidemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283085     DOI: 10.4037/ajcc2013748

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  10 in total

1.  Digital necrosis: a potential risk of high-dose norepinephrine.

Authors:  Rafael Daroca-Pérez; Miguel F Carrascosa
Journal:  Ther Adv Drug Saf       Date:  2017-06-05

2.  Should the norepinephrine maximal dosage rate be greatly increased in late shock?

Authors:  Christos Stefanou; Lakis Palazis; Areti Loizou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-03-04

3.  Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.

Authors:  Christos Stefanou; Christiana Tzortzi; Fotini Georgiou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-12-09

4.  Management of vasopressor induced ischemia.

Authors:  Michael Livesey; Julio J Jauregui; Max C Hamaker; Raymond A Pensy; Christopher G Langhammer; W Andrew Eglseder
Journal:  J Orthop       Date:  2020-10-16

Review 5.  Vasopressor Choice and Timing in Vasodilatory Shock.

Authors:  Patrick M Wieruszewski; Ashish K Khanna
Journal:  Crit Care       Date:  2022-03-22       Impact factor: 9.097

6.  Outcome of patients with septic shock and high-dose vasopressor therapy.

Authors:  Thomas Auchet; Marie-Alix Regnier; Nicolas Girerd; Bruno Levy
Journal:  Ann Intensive Care       Date:  2017-04-20       Impact factor: 6.925

7.  Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock.

Authors:  Tim G Kampmeier; Philip H Arnemann; Michael Hessler; Laura M Seidel; Karsten Becker; Andrea Morelli; Sebastian W Rehberg; Christian Ertmer
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

8.  Timing of administration of epinephrine predicts the responsiveness to epinephrine in norepinephrine-refractory septic shock: a retrospective study.

Authors:  Daisuke Kasugai; Mitsuaki Nishikimi; Kazuki Nishida; Michiko Higashi; Takanori Yamamoto; Atsushi Numaguchi; Kunihiko Takahashi; Shigeyuki Matsui; Naoyuki Matsuda
Journal:  J Intensive Care       Date:  2019-04-05

9.  Factors associated with outcomes of septic shock patients receiving high dose noradrenaline according to three primary infection sites.

Authors:  Kang-Song Wu; Dan-Yan Gu; Ting-Ting Wang; Bu-Wen Yu; Kong-Han Pan; Jian-Cang Zhou
Journal:  J Int Med Res       Date:  2019-09-17       Impact factor: 1.671

10.  Angiotensin II: a new approach for refractory shock management?

Authors:  Antoine Kimmoun; Bruno Levy
Journal:  Crit Care       Date:  2014-12-18       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.